维生素B6和糖尿病及其在抵消高级糖化终产品中的作用
1Department of Biology and Biotechnology "Charles Darwin" Sapienza University of Rome, Rome, Italy.
Vitamins and hormones
|July 12, 2024
概括
维生素B6,包括氧5-酸盐 (PLP),对抗活性氧物种和高级糖化最终产品 (AGEs),可能减少糖尿病发病和并发症. 需要进一步的研究来澄清维生素B6的含量.
科学领域:
- 生物化学 生物化学
- 营养科学 营养科学
- 代谢疾病 代谢疾病
背景情况:
- 维生素B6包括六种可相互转换的维生素,其中氧化5-酸盐 (PLP) 是活性辅因子.
- 维生素B6的维生素对抗活性氧物种和高级糖化最终产品 (AGEs).
- AGEs在糖尿病中积累,破坏大分子并增加血管疾病和癌症的风险.
研究的目的:
- 探索维生素B6,糖尿病和AGE之间的关系.
- 审查当前的知识,并确定关于维生素B6在糖尿病中的作用的开放问题.
- 讨论维生素B6对糖尿病并发症的保护机制.
主要方法:
- 关于维生素B6,糖尿病和AGE的现有研究的文献综述.
- 分析涉及维生素B6代谢的生物化学途径.
- 对维生素B6补充剂和糖尿病的流行病学和临床研究的审查.
主要成果:
- 维生素B6水平与糖尿病相反相关.
- 补充维生素B6可以减少糖尿病发病和血管并发症.
- 维生素B6作为AGE清洁剂,防止AGE诱导的大分子损伤.
结论:
- 维生素B6在减轻糖尿病并发症方面发挥着重要作用,主要是通过AGE清理.
- 将维生素B6与糖尿病发病联系在一起的精确机制需要进一步阐明.
- 维生素B6是治疗糖尿病及其相关风险的潜在治疗点.
关键词:
年龄的 AGEs.高级糖化最终产品的高级糖化.糖尿病 糖尿病 糖尿病PLP PLP 这是一个很好的选择.总理 总理 总理 总理皮里多克萨尔5'-酸盐是什么?皮里多克萨明 (pyridoxamine) 是一种素.维生素B6 维生素B6 是一种维生素.更多相关视频
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Hormones Regulating Blood Glucose
3.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180


